Topic:

Cancer Vaccines

Latest Headlines

Latest Headlines

Cancer vaccine partners J&J, Aduro add $817M pact

Back in May, Johnson & Johnson's Janssen and California-based Aduro Biotech inked a $365 million deal centered on the former's vaccine technology as a treatment for prostate cancer. But J&J is convinced Aduro's platform has the potential to bolster its oncology pipeline in other areas, too.

Immunotherapy combos could provide a new path forward for troubled cancer vaccine field

When John Vansteenkiste of Belgium University Hospitals Leuven reported the full results of GlaxoSmithKline's MAGE-A3 failure at the European Society of Medical Oncology's annual congress last weekend, he wasn't the first to outline a cancer vaccine flop. But he did offer a way out from under the dark cloud hanging over the field, and it's one that some cancer vaccine makers are already embracing.

CureVac inks lung cancer vaccine deal with Boehringer for up to $600M

CureVac has made its second notable deal with Big Pharma this year, this time partnering with Boehringer Ingelheim to offer its investigational lung cancer vaccine in a $45 million deal with potential milestone payments of up to $556 million.

Asterias, Cancer Research UK partner on lung cancer vaccine trial

Asterias Biotherapeutics, a subsidiary of California-based BioTime, is teaming up with nonprofit Cancer Research UK to trial an immunotherapy vaccine to treat patients with non-small cell lung cancer.

Merck KGaA calls it quits on cancer vaccine--again

After a failed attempt to revive its late-stage program for Stimuvax, Merck KGaA is once again throwing in the towel on the cancer vaccine. The German company's biopharma division will cut its two monotherapy studies in the wake of another recent trial failure in Japan, it said late last week.

Immunotherapy vaccine combo cuts recurrence in HER2 breast cancer patients

A new breast cancer vaccine tested in a clinical trial at the University of Texas MD Anderson Cancer Center boosted survival rates in patients with elevated levels of a protein associated with cancer growth, a new study shows.

Amgen submits melanoma-fighter T-Vec to EMA on the heels of its FDA filing

Back in June, Amgen said it was eyeing a U.S. application for its cancer-fighting viral vaccine in the short term but would be looking outside the U.S. as well. After submitting its candidate to the FDA in July, the company now says it's turned over a marketing authorization application to the European Medicines Agency for the melanoma candidate.

Advaxis teams up with Merck to test its vaccine in prostate cancer

Just over a month after striking an immunotherapy pact with AstraZeneca, New Jersey biotech Advaxis is back with another Big Pharma agreement. This time, the company will be teaming up with Merck to test its cancer vaccine, ADXS-PSA, in combination with the latter's checkpoint inhibitor pembrolizumab.

Vaccinogen raises $10M for work on colon cancer vaccine

Frederick, MD-based Vaccinogen has scored $10 million to fund work on its colon cancer candidate, OncoVax.

Clinical failure for Merck KGaA's cancer vaccine dents subpopulation hopes

Back in 2012, researchers flagged some positive results for patient subgroups in a flunked trial of Merck KGaA's cancer vaccine. But now, the vaccine has hit another snag, failing to hit its primary endpoint--as well as three secondary endpoints--in a Japanese trial, partner Oncothyreon said Monday in an SEC filing.